Rosetta Genomics Ltd. (Nasdaq:ROSG) has commercially launched its second microRNA-based molecular diagnostic test, miRview mets, through Rosetta Genomics CLIA-certified lab in Philadelphia.
The test identifies 25 different tumor types, including, but not limited to, the colon, brain, breast, kidney, liver, lung, ovary, pancreas, prostate, and testis. The test measures the expression level of 48 microRNA biomarkers in the tumor.
Earlier this month, Rosetta Genomics commercially launched its first test, the miRview squamous, and it expects to shortly launch its third test, the miRview meso, which differentiates mesothelioma from adenocarcinoma in the lung.
The company said that it expected to able to offer three microRNA-based tests by the end of 2008.
Earlier this month, Rosetta Genomics published its financial report for the third quarter of 2008. The company posted a net loss of $3 million on $705,000 revenue, all of which came from Parkway Clinical Laboratories Inc., which was acquired in July. The company predicts that the newly launched diagnostic tests will boost revenue in the coming quarters.
Rosetta Genomics' share fell 4.2% on Nasdaq yesterday to $1.14, giving a market cap of $14 million.
Published by Globes [online], Israel business news - www.globes-online.com - on December 29, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008